Differing effects of denosumab and alendronate on cortical and trabecular bone
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Vertebral fractures and trabecular bone loss are hallmarks of osteoporosis. However, 80% of fractures are non-vertebral and 70% of all bone loss is cortical and is produced by intracortical remodeling. The resulting cortical porosity increases bone fragility exponentially. Denosumab, a fully human anti-RANKL antibody, reduces the rate of bone remodeling more than alendronate. The aim of this study was to quantify the effects of denosumab and alendronate on cortical and trabecular bone. Postmenopausal women, mean age 61years (range 50 to 70), were randomized double blind to placebo (n=82), alendronate 70mg weekly (n=82), or denosumab 60mg every 6months (n=83) for 12months. Porosity of the compact-appearing cortex (CC), outer and inner cortical transitional zones (OTZ, ITZ), and trabecular bone volume/total volume (BV/TV) of distal radius were quantified in vivo from high-resolution peripheral quantitative computed tomography scans. Denosumab reduced remodeling more rapidly and completely than alendronate, reduced porosity of the three cortical regions at 6months, more so by 12months relative to baseline and controls, and 1.5- to 2-fold more so than alendronate. The respective changes at 12months were [mean (95% CI)]; CC: -1.26% (-1.61, -0.91) versus -0.48% (-0.96, 0.00), p=0.012; OTZ: -1.97% (-2.37, -1.56) versus -0.81% (-1.45, -0.17), p=0.003; and ITZ: -1.17% (-1.38, -0.97) versus -0.78% (-1.04, -0.52), p=0.021. Alendronate reduced porosity of the three cortical regions at 6months relative to baseline and controls but further decreased porosity of only the ITZ at 12months. By 12months, CC porosity was no different than baseline or controls, OTZ porosity was reduced only relative to baseline, not controls, while ITZ porosity was reduced relative to baseline and 6months, but not controls. Each treatment increased trabecular BV/TV volume similarly: 0.25% (0.19, 0.30) versus 0.19% (0.13, 0.30), p=0.208. The greater reduction in cortical porosity by denosumab may be due to greater inhibition of intracortical remodeling. Head to head studies are needed to determine whether differences in porosity result in differing fracture outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mixed-Effects Models in Sand S-PLUS
Pinheiro, J. C., & Bates, D. M. (2000) · Statistics and Computing · doi:10.1007/978-1-4419-0318-1 · Cited by 11,187
Mixed-Effects Models in S and S-PLUS
(2001) · Technometrics · doi:10.1198/tech.2001.s574 · Cited by 9,278 · cited 1×
“Estimates for the changes in porosity and inferential statistics were derived using a random intercept model with subject as the random effect with main effects for treatment, visit, and baseline porosity [23].”
MethodBlack, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
The Abuse of Power: The Pervasive Fallacy of Power Calculations for Data Analysis
Hoenig, J. M., & Heisey, D. M. (2001) · The American Statistician · doi:10.1198/000313001300339897 · Cited by 2,046
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Denosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Mixed-Effects Models in S and S-PLUS
(2000) · Statistics and Computing · doi:10.1007/b98882 · Cited by 930
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Stiffness of compact bone: Effects of porosity and density
Schaffler, M. B., & Burr, D. B. (1988) · Journal of Biomechanics · doi:10.1016/0021-9290(88)90186-8 · Cited by 652 · cited 1×
“A small increase in porosity disproportionately reduces resistance to bending; this is more so in cortical than trabecular bone [42,43].”
Background
Cited by
Compston, J. E., McClung, M. R., & Leslie, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32112-3 · Cited by 2,449
A network of trans-cortical capillaries as mainstay for blood circulation in long bones
Grüneboom, A., Hawwari, I., Weidner, D., Culemann, S., Müller, S., Henneberg, S., Brenzel, A., Merz, S., Bornemann, L., Zec, K., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-018-0016-5 · Cited by 307
Kyung Kim, D., Lee, S., Kim, M., Jeong, Y., & Lee, S. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.127080 · Cited by 57
Unexpected Bone Formation Produced by RANKL Blockade
Portal-Núñez, S., Mediero, A., Esbrit, P., Sánchez-Pernaute, O., Largo, R., & Herrero-Beaumont, G. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.06.003 · Cited by 32
Metadata
- Authors
- Zebaze, R. M., Libanati, C., Austin, M., Ghasem-Zadeh, A., Hanley, D. A., Zanchetta, J. R., Thomas, T., Boutroy, S., Bogado, C. E., Bilezikian, J. P., & Seeman, E.
- Venue
- Bone
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 59
- Pages
- 173-179
- ISSN
- 1873-2763 (ISSN-L)
- 8756-3282
- OpenAlex
- W2009250547
- Cited by
- 155
- References
- 12
- FWCI
- 15.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differing effects of denosumab and alendronate on cortical and trabecular bone. https://app.cochat.ai/papers/10.1016/j.bone.2013.11.016
- The paper
- Zebaze, R. M., Libanati, C., Austin, M., Ghasem-Zadeh, A., Hanley, D. A., Zanchetta, J. R., Thomas, T., Boutroy, S., Bogado, C. E., Bilezikian, J. P., & Seeman, E. (2014). Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone. https://doi.org/10.1016/j.bone.2013.11.016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.